Sabby Management’s Cardiff Oncology CRDF Stock Holding History

Sabby Management’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-25,606	Closed	-$125K	–	126
2018 Q3	$125K	Sell	25,606 -99,486	-80%	-$471K	0.02%	99
2018 Q2	$578K	Buy	+125,092	New	+$2.09M	0.09%	79
2017 Q4	–	Sell	-23,469	Closed	-$1.23M	–	164
2017 Q3	$1.23M	Buy	+23,469	New	+$1.46M	0.08%	70
2016 Q2	–	Sell	-1,181	Closed	-$395K	–	302
2016 Q1	$395K	Sell	1,181 -1,043	-47%	-$355K	0.02%	229
2015 Q4	$865K	Sell	2,224 -554	-20%	-$217K	0.05%	200
2015 Q3	$1.14M	Buy	+2,778	New	+$1.45M	0.05%	220
2015 Q2	–	Sell	-208	Closed	-$102K	–	334
2015 Q1	$102K	Sell	208 -70	-25%	-$29.9K	﹤0.01%	273
2014 Q4	$86K	Hold	278	–	–	﹤0.01%	222
2014 Q3	$92K	Hold	278	–	–	﹤0.01%	234
2014 Q2	$70K	Hold	278	–	–	﹤0.01%	242
2014 Q1	$115K	Hold	278	–	–	0.01%	219
2013 Q4	$115K	Buy	+278	New	+$124K	0.01%	196

Other funds holding CRDF

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Sabby Management's CRDF Position: Q4 2018 in Review

Sabby Management sold out of Cardiff Oncology (CRDF) in Q4 2018, closing a stake of 25,606 shares — an estimated $125K sold.

Sabby Management first reported a position in CRDF in Q4 2013 and held it in 12 quarters. The position peaked at $1.23M in Q3 2017. 26 funds tracked by Wall St. Rank hold CRDF as of Q4 2018.

Sabby Management reported no remaining Cardiff Oncology position as of Q4 2018 after selling out during the quarter.
Sabby Management sold 25,606 Cardiff Oncology shares in Q4 2018, an estimated $125K.
Sabby Management first reported a position in Cardiff Oncology in Q4 2013 and held it in 12 quarters.
Sabby Management's Cardiff Oncology position peaked at $1.23M in Q3 2017.
26 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2018.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.